PT2866825T - Uso de péptidos glp-1 de longa ação - Google Patents
Uso de péptidos glp-1 de longa açãoInfo
- Publication number
- PT2866825T PT2866825T PT137378089T PT13737808T PT2866825T PT 2866825 T PT2866825 T PT 2866825T PT 137378089 T PT137378089 T PT 137378089T PT 13737808 T PT13737808 T PT 13737808T PT 2866825 T PT2866825 T PT 2866825T
- Authority
- PT
- Portugal
- Prior art keywords
- peptides
- long
- acting glp
- glp
- acting
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781 | 2012-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2866825T true PT2866825T (pt) | 2020-07-15 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137378089T PT2866825T (pt) | 2012-07-01 | 2013-06-21 | Uso de péptidos glp-1 de longa ação |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (enExample) |
| EP (3) | EP4406593A3 (enExample) |
| JP (1) | JP6059802B2 (enExample) |
| AU (3) | AU2013286177B2 (enExample) |
| BR (1) | BR112014032938A2 (enExample) |
| CA (1) | CA2877056A1 (enExample) |
| DK (1) | DK2866825T3 (enExample) |
| ES (2) | ES2796839T3 (enExample) |
| HR (2) | HRP20251088T1 (enExample) |
| HU (2) | HUE072859T2 (enExample) |
| MX (3) | MX366405B (enExample) |
| PL (2) | PL3689365T3 (enExample) |
| PT (1) | PT2866825T (enExample) |
| RS (2) | RS60432B1 (enExample) |
| RU (2) | RU2018117557A (enExample) |
| SI (1) | SI2866825T1 (enExample) |
| WO (1) | WO2014005858A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
| MY171146A (en) | 2012-03-22 | 2019-09-27 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| SI2866825T1 (sl) | 2012-07-01 | 2020-07-31 | Novo Nordisk A/S | Uporaba dolgo delujočih peptidov GLP-1 |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| CN110254223B (zh) * | 2014-10-16 | 2022-03-25 | 洋马动力科技有限公司 | 拖拉机 |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| CN120241968A (zh) * | 2017-10-12 | 2025-07-04 | 诺和诺德股份有限公司 | 用于药物治疗的司美鲁肽 |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| MA53076B1 (fr) | 2018-02-02 | 2023-11-30 | Novo Nordisk As | Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| EP3930753A4 (en) * | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR |
| MX2022004779A (es) * | 2019-11-06 | 2022-06-14 | Novo Nordisk As | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. |
| CN114901680B (zh) * | 2019-12-30 | 2024-09-27 | 甘李药业股份有限公司 | 长效glp-1化合物 |
| US20230093542A1 (en) * | 2020-02-18 | 2023-03-23 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| US20240285729A1 (en) * | 2021-06-24 | 2024-08-29 | Gila Therapeutics, Inc. | Methods and kits for inducing satiety and treating metabolic disorders |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| MX2024003872A (es) | 2021-09-27 | 2024-04-19 | Terns Pharmaceuticals Inc | Acidos carboxilicos de benzimidazol como agonistas de glp-1r. |
| EP4422745A1 (en) | 2021-10-25 | 2024-09-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2024544920A (ja) | 2021-11-10 | 2024-12-05 | アイ２オー セラピューティクス，インク． | イオン液体組成物 |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| MX2024010346A (es) | 2022-02-23 | 2024-08-30 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r. |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| WO2025024455A1 (en) | 2023-07-24 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU2002316811A1 (en) | 2001-06-28 | 2003-03-03 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| CA2545034C (en) | 2003-11-20 | 2013-03-05 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| KR101340354B1 (ko) * | 2004-11-12 | 2013-12-11 | 노보 노르디스크 에이/에스 | 안정한 펩티드 제제 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2646400A1 (en) * | 2006-04-14 | 2007-10-25 | Mannkind Corporation | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP5411366B2 (ja) * | 2009-12-16 | 2014-02-12 | ノヴォ ノルディスク アー／エス | 二重アシル化ｇｌｐ−１誘導体 |
| ES2935300T3 (es) * | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) * | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| SI2866825T1 (sl) | 2012-07-01 | 2020-07-31 | Novo Nordisk A/S | Uporaba dolgo delujočih peptidov GLP-1 |
-
2013
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2866825T3 (pl) | <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div> | |
| ZA201406250B (en) | Compositions of glp-1 peptides and preparation thereof | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| EP2857033A4 (en) | PEPTIDE WITH SKIN PERMEATION | |
| TWI561242B (en) | Long-acting peptide analogs | |
| EP2914293A4 (en) | METHOD OF USE OF FVIII POLYPEPTIDE | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| GB201216800D0 (en) | Novel use | |
| IL238651B (en) | Long-acting, single-chain insulin analogs | |
| ZA201503127B (en) | Peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| GB201223114D0 (en) | Novel peptide | |
| GB201217908D0 (en) | Retractable footrest | |
| IL234228B (en) | Compositions of glp-1 peptides and preparation thereof | |
| EP2891663A4 (en) | PEPTIDE DERIVED FROM PSF1 | |
| GB201212463D0 (en) | Novel use | |
| PT3824876T (pt) | Formulações de longa ação de insulinas | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| TWM433525U (en) | Structure of calorifier | |
| GB201207895D0 (en) | Peptides | |
| GB201200623D0 (en) | Peptide | |
| GB201200624D0 (en) | Peptide |